

## **AMENDMENTS TO THE CLAIMS**

**1. (Currently amended)** ~~An~~ A pharmaceutical composition for treating and/or preventing a disease by releasing glycosylphosphatidylinositol (GPI)-anchored protein from the cell surface, said composition comprising  
\_\_\_\_\_ a mutant angiotensin-converting enzyme-containing medicine, of which action mechanism is release of GPI anchored protein from the cell surface. (ACE) consisting of the amino acid sequence of SEQ ID NO: 4 except Glu at position 414 is substituted with Asp; and  
\_\_\_\_\_ a pharmaceutically acceptable carrier.

**2. (Currently amended)** ~~The medicine~~ pharmaceutical composition of claim 1 ~~for preventing and curing, wherein the disease is~~ prion-related diseases.

**3. (Currently amended)** ~~The medicine~~ pharmaceutical composition of claim 1 ~~for preventing and curing, wherein the disease is~~ bacterial infectious diseases.

**4. (Currently amended)** ~~The medicine~~ pharmaceutical composition of claim 1 ~~for preventing and curing, wherein the disease is~~ male infertility due to sperm abnormality.

**5-7. (Canceled)**

**8. (Currently amended)** ~~A mutant angiotensin-converting enzyme to which amino acid mutation is introduced for inactivating peptidase activity~~ (ACE) consisting of the amino acid sequence of SEQ ID NO: 4 except Glu at position 414 is substituted with Asp.

**9-19. (Canceled)**